221 related articles for article (PubMed ID: 27861184)
1. Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.
Roston TM; Van Petegem F; Sanatani S
Curr Opin Cardiol; 2017 Jan; 32(1):78-85. PubMed ID: 27861184
[TBL] [Abstract][Full Text] [Related]
2. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
4. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
Roston TM; Cunningham TC; Sanatani S
Cardiol Young; 2017 Jan; 27(S1):S49-S56. PubMed ID: 28084961
[TBL] [Abstract][Full Text] [Related]
5. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
[TBL] [Abstract][Full Text] [Related]
6. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
[TBL] [Abstract][Full Text] [Related]
7. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA
J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
[TBL] [Abstract][Full Text] [Related]
9. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
[TBL] [Abstract][Full Text] [Related]
10. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
Watanabe H; Knollmann BC
J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
[TBL] [Abstract][Full Text] [Related]
11. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
Kohli U; Aziz Z; Beaser AD; Nayak HM
Pacing Clin Electrophysiol; 2019 Aug; 42(8):1146-1154. PubMed ID: 30912151
[TBL] [Abstract][Full Text] [Related]
12. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation.
Itoh H; Murayama T; Kurebayashi N; Ohno S; Kobayashi T; Fujii Y; Watanabe M; Ogawa H; Anzai T; Horie M
J Electrocardiol; 2021; 69():111-118. PubMed ID: 34656916
[TBL] [Abstract][Full Text] [Related]
13. Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
Hong RA; Rivera KK; Jittirat A; Choi JJ
Pacing Clin Electrophysiol; 2012 Jul; 35(7):794-7. PubMed ID: 22553997
[TBL] [Abstract][Full Text] [Related]
14. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
Pflaumer A; Davis AM
Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
[TBL] [Abstract][Full Text] [Related]
16. Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.
Imberti JF; Underwood K; Mazzanti A; Priori SG
Heart Lung Circ; 2016 Aug; 25(8):777-83. PubMed ID: 26948768
[TBL] [Abstract][Full Text] [Related]
17. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome.
Schneider HE; Steinmetz M; Krause U; Kriebel T; Ruschewski W; Paul T
Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214
[TBL] [Abstract][Full Text] [Related]
18. Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.
Bergeman AT; Wilde AAM; van der Werf C
Card Electrophysiol Clin; 2023 Sep; 15(3):293-305. PubMed ID: 37558300
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
20. BASIC AND CLINICAL INSIGHTS IN CATECHOLAMINERGIC (FAMILIAL) POLYMORPHIC VENTRICULAR TACHYCARDIA.
Márquez MF; Totomoch-Serra A; Rueda A; Avelino-Cruz JE; Gallegos-Cortez A
Rev Invest Clin; 2019; 71(4):226-236. PubMed ID: 31448784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]